Immune Regulation teams with DynPort on COVID-19 drug
The companies will jointly evaluate the potential of ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS)
Read More
Tag: ILR201104
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
